Alzamend Neuro Files 8-K with Corporate Updates

Ticker: ALZN · Form: 8-K · Filed: Jul 9, 2025 · CIK: 1677077

Alzamend Neuro, INC. 8-K Filing Summary
FieldDetail
CompanyAlzamend Neuro, INC. (ALZN)
Form Type8-K
Filed DateJul 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-action, filing, financials

Related Tickers: ALZN

TL;DR

ALZN filed an 8-K on 7/9/25 for corporate changes & financials.

AI Summary

Alzamend Neuro, Inc. filed an 8-K on July 9, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, incorporated in Delaware, is based in Atlanta, GA, and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates significant corporate actions and financial reporting by Alzamend Neuro, Inc., which could impact investors' understanding of the company's structure and financial health.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.

Key Numbers

Key Players & Entities

FAQ

What specific amendments were made to Alzamend Neuro, Inc.'s articles of incorporation or bylaws?

The filing indicates amendments were made, but the specific details of these amendments are not provided in the summary text.

What financial statements are being reported in this 8-K filing?

The filing states that financial statements are included, but the specific statements (e.g., balance sheet, income statement) are not detailed in the provided text.

When was Alzamend Neuro, Inc. incorporated?

Alzamend Neuro, Inc. was incorporated in Delaware.

What is the primary business address of Alzamend Neuro, Inc.?

The primary business address is 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326.

What is the SIC code for Alzamend Neuro, Inc.?

The Standard Industrial Classification (SIC) code for Alzamend Neuro, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 9, 2025 regarding Alzamend Neuro, Inc. (ALZN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing